Resistance to Targeted Therapies in Multiple Myeloma

Multiple Myeloma is an incurable malignancy that becomes resistant to treatment. Targeted therapies, such as Proteasome Inhibitors, Immunomodulatory Drugs, and Monoclonal Antibodies, are approved to be used in combination to overcome resistance. CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors, and BCL-2 inhibitors are undergoing clinical trials. This book will help to develop an understanding of targeted therapies in Multiple Myeloma and provide insights into the mechanism of action and resistance, application of biomarkers and genomics, and possible strategies in overcoming resistance and future development.

Format: Paperback / softback
Length: 154 pages
Publication date: 25 July 2022
Publisher: Springer Nature Switzerland AG

Multiple Myeloma, a relentless malignancy, persists as an incurable disease. As the disease advances, it inevitably acquires resistance to treatment, leading to the development of refractory disease in nearly all patients. The field of targeted therapies offers a diverse array of treatment options, with numerous types employed in combination at different stages of the disease. Approved targeted therapies include Proteasome Inhibitors, Immunomodulatory Drugs, and Monoclonal Antibodies. Second and third-generation drugs are being developed to overcome resistance and possess unique mechanisms of action. Ongoing clinical trials involve CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors, and BCL-2 inhibitors.

This comprehensive book aims to enhance understanding of targeted therapies in Multiple Myeloma. Its primary objective is to present a unique review of the mechanism of action and resistance of various targeted therapies by esteemed experts in the field. The book will serve as a valuable resource for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers.

Within its pages, the book will provide insightful knowledge of the biology of Multiple Myeloma, the mechanisms of action and resistance of targeted therapies, the application of biomarkers and genomics, and potential strategies for overcoming resistance and fostering future development. By delving into these critical aspects, the book aims to empower readers with the knowledge necessary to navigate the complexities of Multiple Myeloma treatment and make informed decisions for patients.

Weight: 273g
Dimension: 235 x 155 (mm)
ISBN-13: 9783030734428
Edition number: 1st ed. 2021